Robinson investigates how care models influence incretin therapy outcomes

Incretin-based therapies, such as GLP-1s and GIPs, have transformed treatment for people with Type II Diabetes (T2D) and obesity. In turn, many clinicians have harnessed these medications to help patients achieve greater weight loss and improved glycemic control. As GLP-1/GIP use continues to rise, UI Health Care Endocrinologist Kathleen Robinson, MD, PhD, wanted to examine whether medical […]

GLP-1 pilot program receives 97% patient approval rating at half-year mark

There is no one-size-fits-all approach to weight management, but recent advancements in GLP-1 based medications offer a new treatment opportunity for patients with obesity and related conditions. UI Weight Management clinicians and members of the Division of Endocrinology and Metabolism Leon Jons, MD, and Amanda Pitts, ARNP, DNP, are helping to lead a new effort […]